Update on the use of pramipexole in the treatment of Parkinson’s disease

Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, SwedenAbstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Radu Constantinescu
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/17db5ca1eeb748cd82866c37b72f19e4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:17db5ca1eeb748cd82866c37b72f19e4
record_format dspace
spelling oai:doaj.org-article:17db5ca1eeb748cd82866c37b72f19e42021-12-02T03:02:30ZUpdate on the use of pramipexole in the treatment of Parkinson’s disease1176-63281178-2021https://doaj.org/article/17db5ca1eeb748cd82866c37b72f19e42008-04-01T00:00:00Zhttp://www.dovepress.com/update-on-the-use-of-pramipexole-in-the-treatment-of-parkinsonrsquos-d-a1019https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, SwedenAbstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events Radu ConstantinescuDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 2, Pp 337-352 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Radu Constantinescu
Update on the use of pramipexole in the treatment of Parkinson’s disease
description Radu ConstantinescuDepartment of Neurology, Sahlgrenska University Hospital, 413 45 Göteborg, SwedenAbstract: Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of Parkinson’s disease (PD). This review addresses the literature concerning pramipexole’s efficacy in treating motor and non-motor symptoms in PD, its impact on the development of dyskinesias and response fluctuations, the issue of neuroprotection, and the risk for developing adverse events such as increased somnolence, attacks of sudden onset of sleep, cardiac valvulopathy and impulse control disturbances.Keywords: pramipexole, Parkinson’s disease, efficacy, adverse events
format article
author Radu Constantinescu
author_facet Radu Constantinescu
author_sort Radu Constantinescu
title Update on the use of pramipexole in the treatment of Parkinson’s disease
title_short Update on the use of pramipexole in the treatment of Parkinson’s disease
title_full Update on the use of pramipexole in the treatment of Parkinson’s disease
title_fullStr Update on the use of pramipexole in the treatment of Parkinson’s disease
title_full_unstemmed Update on the use of pramipexole in the treatment of Parkinson’s disease
title_sort update on the use of pramipexole in the treatment of parkinson’s disease
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/17db5ca1eeb748cd82866c37b72f19e4
work_keys_str_mv AT raduconstantinescu updateontheuseofpramipexoleinthetreatmentofparkinsonamprsquosdisease
_version_ 1718401965598179328